The Food And Drug Administration has delayed advertising guidelines for pharmaceutical social media marketing, and pharma companies are twiddling their thumbs. Twice last month, the head of the FDA's
division of Drug Marketing, Advertising and Communications suggested that little will change. "The process is taking longer than we thought," he said in a New York conference. He said part of the
delay had to do with the agency's concern that social media companies might be ephemeral.
Read the whole story at Advertising Age »